0353 GMT - President Trump's "Liberation Day" tariffs are likely not a big concern for China's healthcare industry, Jefferies analysts say in a research note. Drugs and active pharmaceutical ingredients are exempt from tariffs, and even if Trump imposed any tariffs in the future, most Chinese biotech companies have U.S. partners that are not considered exporters, they say. Contract drug makers, such as the WuXi companies, are in exempt categories as well, they note. "If the exemption were canceled, the tariff would apply to all non-U.S. competitors, while Chinese players would retain cost and efficiency advantages," they say. Medical equipment makers are subject to 54% tariffs, but the analysts reckon the impact will be manageable, as the Chinese makers, such as Mindray Medical International, have low sales exposure to the U.S. (sherry.qin@wsj.com)
(END) Dow Jones Newswires
April 02, 2025 23:53 ET (03:53 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。